research reports and media, page-1072

The RAC Director was always communicating and answering questions and queries on here (hc) for the shareholders which was great. 1 thing he said which surprised me was that a t/o or buyout is always best to do after phase 2 trials and not phase 3. He said u don’t need phase 3 trials if the drug is good enough. A little sideways with me mentioning RAC but does anybody know whether this is the case or not?? If so I wouod have thought that PAR would have companies throwing themselves at them. I know we don’t want a buyout but am interested to hear what other people’s thoughts r on this.